The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence

Abstract EN

Patients with chronic liver diseases (CLD) undergo a range of invasive procedures during their clinical lifetime.

Various hemostatic abnormalities are frequently identified during the periprocedural work-up; including thrombocytopenia.

Thrombocytopenia of cirrhosis is multifactorial in origin, and decreased activity of thrombopoietin has been identified to be a major cause.

Liver is an important site of thrombopoietin production and its levels are decreased in patients with cirrhosis.

Severe thrombocytopenia (platelet counts < 60–75,000/µL) is associated with increased risk of bleeding with invasive procedures.

In recent years, compounds with thrombopoietin receptor agonist activity have been studied as therapeutic options to raise platelet counts in CLD.

We reviewed the use of Eltrombopag, Romiplostim, and Avatrombopag prior to various invasive procedures in patients with CLD.

These agents seem promising in raising platelet counts before elective procedures resulting in reduction in platelet transfusions, and they also enabled more patients to undergo the procedures.

However, these studies were not primarily aimed at comparing bleeding episodes among groups.

Use of these agents had some adverse consequences, importantly being the occurrence of portal vein thrombosis.

This review highlights the need of further studies to identify reliable methods of safely reducing the provoked bleeding risk linked to thrombocytopenia in CLD.